Rheumatol Int. 2025 May 10;45(6):139. doi: 10.1007/s00296-025-05894-4.
ABSTRACT
Systemic lupus erythematosus (SLE) patients have a significantly increased risk of developing cardiovascular disease (CVD). Despite the implementation of preventive measures and treatment of lipid disorders, as well as reduced use of glucocorticoids, CVD remains one of the leading causes of death in this patient group. It is crucial to develop an appropriate CVD risk assessment strategy that considers the distinctive characteristics of this patient population. This paper provides a comprehensive analysis of the methods used to assess CVD risk in SLE patients. It also presents effective strategies for the reduction of the effects of traditional and non-traditional risk factors for atherosclerosis.
PMID:40347239 | DOI:10.1007/s00296-025-05894-4